| 001 | 306242 | ||
| 005 | 20251118113425.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers13143630 |2 doi |
| 024 | 7 | _ | |a pmid:34298855 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8307809 |2 pmc |
| 037 | _ | _ | |a DKFZ-2025-02471 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Shalata, Walid |b 0 |
| 245 | _ | _ | |a Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). |
| 260 | _ | _ | |a Basel |c 2021 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1763462039_1939186 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #DKFZ-MOST-Ca194# |
| 520 | _ | _ | |a The new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 antibody drug, and lenvatinib is a TKI with preferential antiangiogenic activity. We present, to our knowledge, the first reported series of cases consisting of patients with metastatic non-small cell lung cancer and malignant pleural mesothelioma who were treated with several types of chemotherapy combinations and ICIs followed by disease progression. They were subsequently treated with combined immunotherapy and TKI treatment, resulting in a near complete response within a very short time. Clinical responses were supported by in vitro testing of each patient's lymphocytic response to pembrolizumab after pre-exposure of target cancer cells to lenvatinib. |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a NSCLC |2 Other |
| 650 | _ | 7 | |a immune checkpoint inhibitor |2 Other |
| 650 | _ | 7 | |a lenvatinib |2 Other |
| 650 | _ | 7 | |a lung adenocarcinoma |2 Other |
| 650 | _ | 7 | |a malignant pleural mesothelioma |2 Other |
| 650 | _ | 7 | |a multikinase inhibitor |2 Other |
| 650 | _ | 7 | |a pembrolizumab |2 Other |
| 700 | 1 | _ | |a Iraqi, Muhammed |0 0000-0001-5488-0996 |b 1 |
| 700 | 1 | _ | |a Bhattacharya, Baisali |b 2 |
| 700 | 1 | _ | |a Fuchs, Vered |0 0000-0001-5174-8535 |b 3 |
| 700 | 1 | _ | |a Roisman, Laila C |0 0000-0001-8455-9327 |b 4 |
| 700 | 1 | _ | |a Cohen, Ahron Yehonatan |b 5 |
| 700 | 1 | _ | |a Massalha, Ismaell |b 6 |
| 700 | 1 | _ | |a Yakobson, Alexander |b 7 |
| 700 | 1 | _ | |a Prasad, Manu |b 8 |
| 700 | 1 | _ | |a Elkabets, Moshe |0 0000-0003-3634-9098 |b 9 |
| 700 | 1 | _ | |a Porgador, Angel |b 10 |
| 700 | 1 | _ | |a Peled, Nir |b 11 |
| 773 | _ | _ | |a 10.3390/cancers13143630 |g Vol. 13, no. 14, p. 3630 - |0 PERI:(DE-600)2527080-1 |n 14 |p 3630 |t Cancers |v 13 |y 2021 |x 2072-6694 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2022 |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-14 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-14 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-14 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2022 |d 2024-12-14 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-He78)W500-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W510-20160331 |
| 980 | 1 | _ | |a EXTERN4COORD |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::